Core Viewpoint - A class action lawsuit has been filed against Quantum Biopharma Ltd. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by February 23, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that Quantum and certain officers and/or directors engaged in securities fraud [1]. - Defendants, including CIBC World Markets and Royal Bank of Canada, are accused of placing thousands of spoofed sell orders to create a false impression of Quantum's stock price decline [1]. - These manipulative orders allegedly deceived investors into selling their shares at artificially low prices, allowing the Defendants to purchase shares at depressed levels for profit [1]. Group 2: Legal Representation - Pomerantz LLP, a prominent law firm specializing in corporate and securities class litigation, is representing the affected investors [1]. - The firm has a long history of fighting for victims of securities fraud and has recovered numerous multimillion-dollar damages awards [1].

Core Viewpoint - Hilcorp Energy Company has announced its 2026 capital project plan for the San Juan Basin Royalty Trust, estimating capital expenditures of approximately $14.0 million for the year [1]. Group 1: 2026 Capital Expenditure Plan - The 2026 Plan includes 32 projects, with approximately $11.5 million allocated to nine new vertical drill projects and six new horizontal drill projects [1]. - The remaining budget includes approximately $2.0 million for 17 recompletions and workovers, and about $0.5 million for facilities projects related to natural gas compression [1]. Group 2: Historical Expenditures - For 2025, Hilcorp projected capital expenditures of approximately $9.0 million, with actual expenditures totaling around $8.3 million [1]. - The breakdown of 2025 expenditures includes approximately $4.0 million on seven drilling projects and about $4.3 million on 23 recompletions and workovers [1].

Core Insights - AI is transforming the decision-making process for significant life events, particularly in home buying, where quick, clear, and accurate information is crucial [1] Company Overview - Zillow is collaborating with Google NotebookLM to provide home-buying guidance through a personalized AI research tool, enhancing user experience by offering reliable information with direct citations [2][7] - The partnership aims to meet the needs of home buyers by providing trusted information at the beginning of their home-buying journey [3][6] Product Features - The featured notebook in NotebookLM allows users to ask questions about various home-buying topics, such as preapproval versus prequalification and post-offer processes, helping to alleviate confusion and stress [4] - NotebookLM includes features like "Audio Overviews," which convert written guides into engaging audio formats, making information more accessible [5] Market Position - Zillow is recognized as the most visited real estate app and website in the U.S., connecting millions of consumers with innovative technology and trusted professionals [11] - The company's ecosystem encompasses the entire home journey, from dreaming and shopping to renting, buying, selling, and financing [12]

Core Viewpoint - FIBRA Prologis announces that its subsidiary Terrafina has received authorization from the CNBV for the cancellation of its CBFIs registration in the National Securities Registry, leading to the delisting of these certificates from the Mexican Stock Exchange [1] Group 1: Authorization and Delisting - Terrafina received official notice from the CNBV on February 18, 2026, authorizing the cancellation of its CBFIs registration in the RNV [1] - The decision was based on resolutions from a CBFI holders' meeting held on December 1, 2025, where the cancellation was approved [1] - Following this authorization, Terrafina has delisted its CBFIs from the BMV, ceasing their listing and trading [1] Group 2: Tender Offer and Payment Trust - FIBRA Prologis previously conducted a tender offer for the acquisition of Terrafina's CBFIs, which concluded on November 12, 2025 [1] - On February 16, 2026, FIBRA Prologis established a payment trust to facilitate the sale of Terrafina's CBFIs for holders who did not participate in the tender offer, allowing them to sell at the same price of MXN$42.5 per CBFI for six months [1] Group 3: Company Profile - FIBRA Prologis is a leading owner and operator of Class A industrial real estate in Mexico, with a portfolio of 515 investment properties totaling 87.0 million square feet (8.1 million square meters) as of September 30, 2025 [1] - The portfolio includes 348 logistics and manufacturing facilities in primary industrial markets, comprising 65.7 million square feet (6.1 million square meters) of Gross Leasable Area (GLA) [1] - Additionally, it holds 167 buildings totaling 21.3 million square feet (2.0 million square meters) of non-strategic assets in other markets [1]

(loss)$000s4,6841,80311,506(15,723)Net loss$000s(85,559)(17,730)(198,847)(121,533)Loss per share$/share(0.10)(0.04)(0.30)(0.34)Adjusted loss1$000s(37,779)(24,995)(122,920)(111,221)Adjusted loss per share1$/share(0.05)(0.06)(0.18)(0.31)Cash flow used in operating activities$000s(34,310)(9,223)(83,591) (82,501)Cash and cash equivalents$000s63,24019,00163,24019,001Drillingmeters13,1938,08736,51432,376Gold producedoz5,6746,35931,93026,264Gold ounces sold1oz5,4779,05328,19621,527Average realized gold price2$/oz3 ...

Core Insights - Coty Inc. reported a net loss of $126.9 million for Q2 FY 2026, significantly missing the consensus estimate of $0.18 EPS by $0.04, resulting in a 22% earnings surprise [1][1][1] - The company's like-for-like revenue declined approximately 3%, contrasting with previous guidance of low-single-digit growth, marking a notable deviation from industry peers who reported stable or improving margins [1][1][1] - Following the earnings miss, Coty withdrew its full-year FY 2026 guidance and introduced a new turnaround strategy called "Coty. Curated." under interim CEO Markus Strobel, aimed at refocusing on core brands [1][1][1] Company Performance - Coty's $126.9 million loss is an outlier in the beauty and personal care sector, where competitors like Estée Lauder, L'Oréal, and Shiseido have shown resilience and growth [1][1][1] - The stock price fell approximately 15% in after-hours and pre-market trading, reaching a 52-week low of $2.66 [1][1][1] - Prior to the earnings announcement, management had expressed optimism about Q2 performance, indicating a significant gap between public expectations and actual results [1][1][1]

Core Viewpoint - Aimco plans to report its fourth quarter 2025 earnings on March 2, 2026, after market close, following the approval of its Plan of Sale and Liquidation aimed at maximizing shareholder returns [1]. Group 1: Earnings Announcement - Aimco will release its fourth quarter 2025 results on March 2, 2026, after the market closes [1]. - The earnings release will be accessible in the Investor Relations section of Aimco's website [1]. Group 2: Strategic Liquidation - On February 6, 2026, Aimco's common stockholders approved the Plan of Sale and Liquidation [1]. - The strategic liquidation is intended solely to maximize shareholder returns [1]. - Aimco plans to sell all assets in an orderly manner and return net proceeds from asset sales and cash on hand to stockholders, after settling liabilities and creating necessary reserves [1]. Group 3: Company Background - Prior to the liquidation plan, Aimco focused on real estate investments, particularly in the multifamily sector within targeted U.S. markets [1]. - The company aimed to enhance outcomes through human capital and create substantial value for investors, teammates, and communities [1].

Core Insights - Boardwalk Real Estate Investment Trust reported strong financial results for 2025, with a profit of $196.9 million and an increase in Funds From Operations (FFO) per Unit by 11.2% to $4.65, alongside an 11.1% increase in monthly distributions to $1.80 per Unit for March, April, and May 2026 [1][2][5] Financial Performance - For Q4 2025, the operating margin improved to 65.4%, a 200 basis point increase from the same period last year, with Same Property Net Operating Income (NOI) rising by 9.0% to $404.3 million [1][2] - The Trust's total NOI for the year was $417.6 million, reflecting a 9.2% increase year-over-year [1] - The Trust experienced a loss of $50.8 million in Q4 2025, contrasting with a profit of $65.9 million in Q4 2024 [2][3] Rental Revenue and Occupancy - Same property rental revenue grew by 4.5% in Q4 2025, with an average occupancy rate of 97.6%, slightly down from 98.0% in Q4 2024 [1][2] - The average occupied rent increased to $1,590 in December 2025, marking an $8 improvement from September 2025 and a $66 increase from December 2024 [1][2] Capital Allocation and Acquisitions - The Trust tactically redeployed $57.3 million under its Normal Course Issuer Bid (NCIB) in 2025 and completed acquisitions totaling $551.5 million for six communities, adding 1,376 suites to its portfolio [1][4] - Dispositions of non-core communities generated gross proceeds of $277.6 million, with a focus on optimizing capital allocation [1][4] Balance Sheet and Liquidity - The debt to total assets ratio stood at 42.3%, up from 40.6% in 2024, while the debt to EBITDA ratio improved to 9.99x [1][2] - The Trust maintained a strong liquidity position with approximately $466 million available at the end of Q4 2025 [1][2] 2026 Financial Guidance - The Trust anticipates Same Property NOI growth between 1.5% and 4.5% for 2026, with FFO projected to be between $4.65 and $4.90 per Unit [1][5] - The outlook remains positive, driven by demand for affordable housing and strategic capital deployment [1][5]

Core Insights - Johnson & Johnson announced promising results from the Phase 1b/2 OrigAMI-4 study, showing a 56% overall response rate for RYBREVANT FASPRO™ in first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) [1][2] - The study demonstrated a 10% complete response rate and a clinical benefit rate of 74%, indicating significant antitumor activity compared to current standards of care [1][2] - The combination of subcutaneous amivantamab and pembrolizumab targets key drivers of tumor growth and resistance, suggesting a potential shift in treatment paradigms for HNSCC [1][2] Study Results - In Cohort 2 of the OrigAMI-4 study, the confirmed overall response rate was 56% (22 out of 39 patients), with 6 complete responses and 18 partial responses [1] - At a median follow-up of 10.4 months, 46% of patients remained on treatment, and tumor shrinkage was observed in 82% of patients [1] - The median progression-free survival was reported at 7.7 months, with a median time to first response of 9.7 weeks [1] Safety Profile - The safety profile of RYBREVANT FASPRO™ combined with pembrolizumab was consistent with individual agents, with no new safety signals identified [1] - Common treatment-emergent adverse events included rash (49%), paronychia (46%), and hypoalbuminemia (41%), with 15% of patients experiencing administration-related reactions [1][2] - Treatment discontinuation due to adverse events occurred in four patients, indicating manageable safety concerns [1] Industry Context - HNSCC is an aggressive cancer type, with current standard treatments yielding low response rates (approximately 18% for PD-1 monotherapy) [1][2] - The introduction of RYBREVANT FASPRO™ represents a significant advancement in addressing unmet needs in HNSCC treatment, particularly for HPV-unrelated cases [1][2] - Ongoing studies, including the Phase 3 OrigAMI-5 study, will further evaluate the efficacy of RYBREVANT FASPRO™ in combination with carboplatin and pembrolizumab [1][2]

Government of Ontario nominee appointed to the Board of Directors of Hydro One Limited [Accessibility Statement] Skip NavigationTORONTO, Feb. 19, 2026 /PRNewswire/ - Hydro One Limited (Hydro One) announced today that the Government of Ontario's nominee Deb Hutton has been appointed to the company's Board of Directors, effective today. Ms. Hutton will fill the board vacancy created when Cherie Brant did not stand for re-election at the company's 2025 annual general meeting of shareholders."We welcome Deb Hut ...